The global demand for Ioversol Market is presumed to reach the market size of nearly USD 2.20 BN by 2028 from USD 1.46 BN in 2021 with a CAGR of 6.1% under the study period 2022 - 2028.
Ioversol refers to a white to off-white crystalline powder that smells like crystalline sulphide. It belongs to the class of medications known as radiopaque contrast agents. This non-ionic radiological contrast agent contains Iodine, a chemical that can absorb x-rays. Ioversol enhances the visibility of the body's blood vessels, organs, and other non-bony tissues during radiologic (x-ray) examinations such as CT scans. Further, it is also injected via IV into a vein or artery (Intravenous). The substance is largely used to treat, manage, prevent, and enhance conditions related to the heart, brain, and blood vessels.
Market Dynamics
The imaging and x-ray business, which is expanding quickly, is the key driver of the ioversol market. The main factors influencing the expansion of the ioversol industry include challenges and diseases associated with bones, an increase in accidents, and kidney-related issues. The x-ray business and, consequently, the ioversol market are growing at a rapid rate due to the rising prevalence of cardiovascular illnesses. The ageing population, which is more susceptible to orthopaedic disorders than younger populations, is another factor driving the growth of the worldwide ioversol market. The demand for ioversol, however, may be hampered in the near future by variables including allergic responses to the usage of ioversol, edoema, breathing difficulties, rapid weight gain, joint or muscle discomfort or weakness, nausea, sweating, etc.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of ioversol. The growth and trends of ioversol industry provide a holistic approach to this study.
Market Segmentation
This section of the ioversol market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Ioversol 34% Injectable Solution (Optiray 160)
- Ioversol 51% Injectable Solution (Optiray 240)
- Ioversol 64% Injectable Solution (Optiray 300)
- Ioversol 68% Injectable Solution (Optiray 320)
- Ioversol 74% Injectable Solution (Optiray 350)
By Application
- X-Ray (Angiography, Urography, Tomography, Others)
- CT Scan
- Brain Disorders
- Blood Vessel Disorders
- Heart Disorders
- Others
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Ioversol market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Ioversol Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the ioversol market include Liebel-Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co., Mallinckrodt Pharmaceuticals, Ultraject, China Resources Pharmaceutical (Shanghai) Co., HB Ocean, Novalek Pharmaceuticals Pvt. Ltd., Stellence Pharmscience Pvt. Ltd., A.S. Joshi & Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
